MX384990B - Selectividad eficaz de proteínas recombinantes. - Google Patents

Selectividad eficaz de proteínas recombinantes.

Info

Publication number
MX384990B
MX384990B MX2017002203A MX2017002203A MX384990B MX 384990 B MX384990 B MX 384990B MX 2017002203 A MX2017002203 A MX 2017002203A MX 2017002203 A MX2017002203 A MX 2017002203A MX 384990 B MX384990 B MX 384990B
Authority
MX
Mexico
Prior art keywords
expression
recombinant proteins
mammalian
invention includes
gpt
Prior art date
Application number
MX2017002203A
Other languages
English (en)
Spanish (es)
Other versions
MX2017002203A (es
Inventor
Darya Burakov
Dipali Deshpande
Gang Chen
James Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017002203A publication Critical patent/MX2017002203A/es
Publication of MX384990B publication Critical patent/MX384990B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2017002203A 2014-08-19 2015-08-19 Selectividad eficaz de proteínas recombinantes. MX384990B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462039416P 2014-08-19 2014-08-19
PCT/US2015/045793 WO2016028838A1 (en) 2014-08-19 2015-08-19 Efficient selectivity of recombinant proteins

Publications (2)

Publication Number Publication Date
MX2017002203A MX2017002203A (es) 2017-05-22
MX384990B true MX384990B (es) 2025-03-14

Family

ID=55347784

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017002203A MX384990B (es) 2014-08-19 2015-08-19 Selectividad eficaz de proteínas recombinantes.
MX2021009154A MX2021009154A (es) 2014-08-19 2017-02-17 Selectividad eficaz de proteinas recombinantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009154A MX2021009154A (es) 2014-08-19 2017-02-17 Selectividad eficaz de proteinas recombinantes.

Country Status (27)

Country Link
US (4) US9732357B2 (enExample)
EP (2) EP3183359B1 (enExample)
JP (4) JP7115851B2 (enExample)
KR (2) KR102556383B1 (enExample)
CN (2) CN113293139B (enExample)
AR (1) AR102333A1 (enExample)
AU (3) AU2015305565B9 (enExample)
CA (1) CA2957036A1 (enExample)
CY (1) CY1124079T1 (enExample)
DK (1) DK3183359T3 (enExample)
EA (1) EA035340B1 (enExample)
ES (1) ES2849728T3 (enExample)
HR (1) HRP20210301T1 (enExample)
HU (1) HUE054069T2 (enExample)
IL (3) IL287020B (enExample)
LT (1) LT3183359T (enExample)
MA (1) MA40371B1 (enExample)
MX (2) MX384990B (enExample)
MY (1) MY191745A (enExample)
PL (1) PL3183359T3 (enExample)
PT (1) PT3183359T (enExample)
RS (1) RS61371B1 (enExample)
SG (2) SG11201701121UA (enExample)
SI (1) SI3183359T1 (enExample)
SM (1) SMT202100054T1 (enExample)
TW (3) TWI832364B (enExample)
WO (1) WO2016028838A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
WO2019157395A1 (en) 2018-02-08 2019-08-15 Applied Stemcells, Inc Methods for screening variant of target gene
CN114585597A (zh) 2019-10-23 2022-06-03 佳能株式会社 制造陶瓷制品的方法和陶瓷制品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1392859B1 (en) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US7192737B2 (en) 2002-03-29 2007-03-20 Xoma Technology Ltd. Methods and materials for increasing expression of recombinant polypeptides
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
JP2005027599A (ja) 2003-07-09 2005-02-03 Nara Institute Of Science & Technology 植物由来遺伝子を用いた遺伝子導入植物の選抜法
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
AR064200A1 (es) 2006-12-07 2009-03-18 Dow Agrosciences Llc Genes marcadores seleccionables
ES2522615T3 (es) 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Regiones de expresión y estabilidad potenciadas
KR100927803B1 (ko) * 2007-11-23 2009-11-23 한국생명공학연구원 식물 형질전환체를 선별하기 위한 마커로서 ｇｐｔ 유전자
ES2570853T3 (es) * 2007-12-07 2016-05-20 Zymogenetics Inc Moléculas de anticuerpo humanizadas específicas para IL-31
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US8927249B2 (en) * 2008-12-09 2015-01-06 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas

Also Published As

Publication number Publication date
HRP20210301T1 (hr) 2021-04-02
AU2015305565B9 (en) 2020-05-21
TW202124716A (zh) 2021-07-01
KR20220080215A (ko) 2022-06-14
MA40371B1 (fr) 2021-03-31
JP7115851B2 (ja) 2022-08-09
SMT202100054T1 (it) 2021-03-15
AU2023200752A1 (en) 2023-03-09
BR112017003074A2 (pt) 2018-03-06
MY191745A (en) 2022-07-13
DK3183359T3 (da) 2021-02-01
EP3901274A1 (en) 2021-10-27
MA40371A (fr) 2017-06-28
AU2023200752B2 (en) 2024-02-29
IL287020B (en) 2022-09-01
CN107075549A (zh) 2017-08-18
TW201615833A (zh) 2016-05-01
TWI777374B (zh) 2022-09-11
US10457959B2 (en) 2019-10-29
CA2957036A1 (en) 2016-02-25
IL295361B1 (en) 2023-04-01
EA201790241A1 (ru) 2017-06-30
IL250531A0 (en) 2017-03-30
IL287020A (en) 2021-12-01
US20200063159A1 (en) 2020-02-27
CN113293139A (zh) 2021-08-24
IL295361A (en) 2022-10-01
AU2020205336A1 (en) 2020-08-06
IL250531B (en) 2021-10-31
JP2017525368A (ja) 2017-09-07
US9732357B2 (en) 2017-08-15
SI3183359T1 (sl) 2021-03-31
AU2020205336B2 (en) 2022-11-10
SG11201701121UA (en) 2017-03-30
US20160053280A1 (en) 2016-02-25
MX2017002203A (es) 2017-05-22
JP2024166420A (ja) 2024-11-28
US20210340564A1 (en) 2021-11-04
IL295361B2 (en) 2023-08-01
ES2849728T3 (es) 2021-08-20
CN113293139B (zh) 2025-04-29
EP3183359A4 (en) 2018-04-04
CN107075549B (zh) 2021-04-20
JP7260510B2 (ja) 2023-04-18
JP2023076667A (ja) 2023-06-01
TWI832364B (zh) 2024-02-11
LT3183359T (lt) 2021-02-25
PL3183359T3 (pl) 2021-08-02
JP7561232B2 (ja) 2024-10-03
KR102406976B1 (ko) 2022-06-10
EP3183359B1 (en) 2020-12-16
AU2015305565B2 (en) 2020-04-30
JP2020174681A (ja) 2020-10-29
MX2021009154A (es) 2021-09-10
PT3183359T (pt) 2021-02-03
EP3183359A1 (en) 2017-06-28
SG10201707859RA (en) 2017-10-30
US20170335341A1 (en) 2017-11-23
CY1124079T1 (el) 2022-05-27
RS61371B1 (sr) 2021-02-26
EA035340B1 (ru) 2020-05-29
AR102333A1 (es) 2017-02-22
KR102556383B1 (ko) 2023-07-17
KR20170055481A (ko) 2017-05-19
US11085053B2 (en) 2021-08-10
TWI719945B (zh) 2021-03-01
WO2016028838A1 (en) 2016-02-25
TW202246506A (zh) 2022-12-01
HUE054069T2 (hu) 2021-08-30
AU2015305565A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
MX2022013540A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MX373035B (es) Trastornos neurodegenerativos.
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
BR112018005464A2 (pt) expressão de proteínas contendo fc
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
BR112018009097A2 (pt) spodoptera frugiperda resistente a vip3a
EA201790360A1 (ru) Получение полностью процессированного и функционального фактора x в фурин-секретирующей системе экспрессии млекопитающего
EP4467565A3 (en) Anti-tnf alpha antibody formulations
EP3700546C0 (en) Wnt5a peptides in reduction of cancer stem cells